LY-544344 Eli Lilly

IDrugs

Volumn 8, Issue 9, 2005, Pages 755-762

  Danysz, Wojciech ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 4 METHYLPENTANOYLAMINO)BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 (2 AMINOPROPIONYLAMINO)BICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 (2' AMINOPROPIONYLAMINO) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 CARBOXYLIC ACID; 2 AMINO 2 (CARBOXY 3 METHYLBUTYLAMINOCARBONYL)BICYCLO[3.1.0]HEXANE 6 CARBOXYLIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 AMINOBICYCLO[3.1.0]HEXANE 2,6 CARBOXYLIC ACID 2 (2' METHOXY)BENZYL ESTER; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIS(5 METHYL 2 OXO 1,3 DIOXOLEN 4 YLMETHYL) 2 AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLATE ETHANESULFONIC ACID; CHOLECYSTOKININ; CLONIDINE; DIAZEPAM; DIZOCILPINE; DOPAMINE; EGLUMETAD; HEXOBARBITAL; KETAMINE; LORAZEPAM; LY 314582; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MGS 009; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PHENCYCLIDINE; PRODRUG; SEROTONIN UPTAKE INHIBITOR; TALAGLUMETAD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTRAINDICATION; DRUG HYDROLYSIS; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; GENERALIZED ANXIETY DISORDER; HUMAN; IC 50; LEARNING DISORDER; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATENT; PSYCHOMOTOR DISORDER; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ALANINE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BICYCLO COMPOUNDS; CLINICAL TRIALS; HUMANS; PRODRUGS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 24644454767     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. 248255 LY-354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL, Burnett JP, Belegaje R, Bleakman D, Monn JA NEUROPHARMACOLOGY 1997 36 1 1-12
2. 253438 Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR J MED CHEM 1997 40 4 528-537
3. 371963 Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Moghaddam B, Adams BW SCIENCE 1998 281 1349-1352
4. 373553 Pharmacology and functions of metabotropic glutamate receptors. Conn PJ, Pin JP ANNU REV PHARMACOL TOXICOL 1997 37 205-237
5. 378246 Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Schoepp DD, Jane DE, Monn JA NEUROPHARMACOLOGY 1999 38 10 1431-1476
6. 378957 LY-354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Shekhar A, Keim SR NEUROPHARMACOLOGY 2000 39 7 1139-1146
7. 378966 Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Spooren WP, Gasparini F, van der Putten H, Koller M, Nakanishi S, Kuhn R EUR J PHARMACOL 2000 397 1 R1-R2
8. 378967 Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Klodzinska A, Chojnacka-Wojcik E, Palucha A, Branski P, Popik P, Pilc A NEUROPHARMACOLOGY 1999 38 12 1831-1839
9. 378990 The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Vandergriff J, Rasmussen K NEUROPHARMACOLOGY 1999 38 2 217-222
10. 412794 Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ J PHARMACOL EXP THER 1998 284 2 651-660
11. 466147 Metabotropic Glutamate Receptors - Fourth International Meeting (Part II), Taormina, Italy. No author listed IDDB MEETING REPORT 2002 September 15-20
12. 472819 The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Petralia RS, Wang YX, Niedzielski AS, Wenthold RJ NEUROSCIENCE 1996 71 4 949-976
13. 475898 LY-354740 (Eli Lilly). Pilc A IDRUGS 2003 6 1 66-71
14. 510174 Evaluation of the cognitive and psychomotor profile of a novel anxiolytic, LY544344, compared to lorazepam in normal volunteers. Boyle J, Trick L, Soo-ampon S, Lilley S, Levine L, Hindmarch I EUR NEUROPSYCHOPHARMACOL 2003 13 4 Suppl S365
15. 2A receptors in rat prelimbic cortex. Wright RA, Schoepp DD ABSTR SOC NEUROSCI 2003 33 Abs 847.5
16. 553097 Prodrugs: Effective Solutions for Solubility, Permeability and Targeting Challenges. Hu L IDRUGS 2004 7 8 736-742
17. 558712 GPCR allosterism and accessory proteins: New Insights into drug discovery. Henry B IDRUGS 2004 7 9 819-821
18. 575094 Society for Neuroscience - 34th Annual Meeting. Phillips T, Mackonochie M IDRUGS 2004 7 12 1067-1069
19. 582652 Pharmacodynamics of a novel anxiolytic (LY544344). Boyle J, Trick L, Soo-ampon S, Lilley S, Levine L, Dellva MA INT J NEUROPSYCHOPHARMACOL 2004 7 Suppl 1 Abs P02.269
20. 582677 Oral efficacy of the mGlut2/3 receptor agonist LY544344 in animal models of psychosis and anxiety. McKinzie DL, Knitowski KM, Hart JC, Johnson BG, Schoepp DD INT BEHAV NEUROSCI SOC 2004 13 Abs 81
21. 582680 Action of the metabotropic glutamate type II receptor agonist LY544344 on panic and anxiety induced by cholecystokinin tetrapeptide in healthy volunteers. Kellner M, Muhtz C, Yassouridis A, Stark K, Arlt J, Wiedemann K PROC ANN MEET DTSCH GES PSYCHIATRIE PSYCHOTHERAPIE NERVENHEILKUNDE 2004 November 25 Abs 0385
22. 591636 Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A PSYCHOPHARMACOLOGY (BERL) 2004 179 1 303-309
23. 591637 Anxiolytic-like activity of the mGlu2/3 receptor agonist LY-354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Linden AM, Shannon H, Baez M, Yu JL, Koester A, Schoepp DD PSYCHOPHARMACOLOGY (BERL) 2004 179 1 284-291
24. 591642 Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist LY-354740 in the fear-potentiated startle paradigm in humans. Grillon C, Cordova J, Levine LR, Morgan CA 3rd PSYCHOPHARMACOLOGY (BERL) 2003 168 4 446-454
25. 591643 The mGlu2/3 receptor agonist, LY-354740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. Swanson CJ, Perry KW, Schoepp DD J NEUROCHEM 2004 88 1 194-202
26. 591644 Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent. Higgins GA, Ballard TM, Kew JN, Richards JG, Kemp JA, Adam G, Woltering, T, Nakanishi S, Mutel V NEUROPHARMACOLOGY 2004 46 7 907-917
27. 591646 Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential location relative to pre- and postsynaptic sites. Tamaru Y, Nomura S, Mizuno N, Shigemoto R NEUROSCIENCE 2001 106 3 481-503
28. 591647 Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD NAT REV DRUG DISCOV 2005 4 2 131-144
29. 591648 Metabotropic glutamate receptors - important modulators of nociception and pain behavior. Neugebauer V PAIN 2002 98 1-2 1-8
30. 591651 The ups and downs of addiction: Role of metabotropic glutamate receptors. Kenny PJ, Markou A TRENDS PHARMACOL SCI 2004 25 5 265-272
31. 591653 Distribution of the mRNA for a metabotropic glutamate receptor mGluR3 in the rat brain - an in situ hybridization study. Ohishi H, Shigemoto R, Nakanishi S, Mizuno N J COMP NEUROL 1993 335 2 252-266
32. 591669 Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: An immunohistochemical study with a monoclonal antibody. Ohishi H, Neki A, Mizuno N NEUROSCI RES 1998 30 1 65-82
33. 591672 Anxiolytic activity of the mGlu2/3 receptor agonist LY-354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Linden AM, Greene SJ, Bergeron M, Schoepp DD NEUROPSYCHOPHARMACOLOGY 2004 29 3 502-513
34. 591673 Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Walker DL, Rattiner LM, Davis M BEHAV NEUROSCI 2002 116 6 1075-1083
35. 591677 Activation of metabotropic glutamate 2/3 mGlu2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. Homayoun H, Jackson ME, Moghaddam B J NEUROPHYSIOL 2005 93 4 1989-2001
36. 591678 Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Aultman JM, Moghaddam B PSYCHOPHARMACOLOGY (BERL) 2001 153 3 353-364
37. 591679 Effects of the mGluR2/3 agonist LY-354740 on computerized tasks of attention and working memory in marmoset monkeys. Spinelli S, Ballard T, Gatti-McArthur S, Richards GJ, Kapps M, Woltering T, Wichmann J, Stadler H, Feldon J, Pryce CR PSYCHOPHARMACOLOGY (BERL) 2005 179 1 292-302
38. 591683 Anxiolytic-like activity of MGS0039, a potent group II metabotropic glutamate receptor antagonist, in a marble-burying behavior test. Shimazaki T, Iijima M, Chaki S EUR J PHARMACOL 2004 501 1-3 121-125
39. 613476 Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY364740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: Preliminary results. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K PSYCHOPHARMACOLOGY (BERL) 2005 179 1 310-315
40. 613562 Pivotal research centers. 2005 February 01 INTERNET SITE http://www.pivotalresearch.com
41. 613563 Overview of clinical trials at the Technische Universitat Dresden. 2005 February 01 INTERNET SITE www.psylux.psych.tu-dresden.de
42. 613565 University of Florida College of Medicine. Funding awards February 2003. INTERNET SITE http://www.med.ufl.edu
43. 613566 The master switch. Singer E NEW SCIENTIST 2004 March 06 2437 35-37